Trevi Therapeutics Inc Share Price Today: Live Updates & Key Insights

Trevi Therapeutics Inc share price today is $10.59, up -0.84%. The stock opened at $10.765 against the previous close of $10.7, with an intraday high of $11.075 and low of $10.38.

Trevi Therapeutics Inc Share Price Chart

Trevi Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Trevi Therapeutics Inc Share Price Performance

$10.59 -0.0084(-0.84%) TRVI at 23 Mar 2026 03:34 PM Biotechnology
Lowest Today 10.38
Highest Today 11.075
Today’s Open 10.765
Prev. Close 10.7
52 Week High 14.39
52 Week Low 4.85
Day’s Range: Low 10.38 High 11.075
52-Week Range: Low 4.85 High 14.39
1 day return -
1 Week return -5.01
1 month return -4.5
3 month return -16.79
6 month return +24.12
1 year return +65.88
3 year return +484.02
5 year return +274.55
10 year return -

Trevi Therapeutics Inc Institutional Holdings

NEA Management Company, LLC 10.31

Frazier Life Sciences Management, L.P. 8.00

BlackRock Inc 7.72

FMR Inc 5.07

Vanguard Group Inc 5.02

Vivo Capital, LLC 3.97

Marshall Wace Asset Management Ltd 3.57

Morgan Stanley - Brokerage Accounts 3.35

AllianceBernstein L.P. 3.35

Rubric Capital Management LP 2.94

Vanguard Total Stock Mkt Idx Inv 2.67

MPM Oncology Impact Management LP 2.66

Wellington Management Company LLP 2.65

Viking Global Investors LP 2.49

Orbimed Advisors, LLC 2.49

Octagon Capital Advisors LP 2.20

Eventide Asset Management, LLC 2.05

Eventide Healthcare & Life Sciences I 2.05

Fidelity Select Biotechnology 1.98

Geode Capital Management, LLC 1.88

Siren, L.L.C. 1.78

State Street Corp 1.73

iShares Russell 2000 ETF 1.73

Logos Global Management LP 1.72

MEDICAL BioHealth EUR Acc 1.09

AB Small Cap Growth A 1.03

Fidelity Small Cap Growth 1.01

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Biotech Growth Ord 0.80

Fidelity Select Health Care 0.78

Fidelity Small Cap Index 0.70

Principal SmallCap Growth I Instl 0.63

iShares Russell 2000 Growth ETF 0.59

Fidelity Small Cap Growth K6 0.50

iShares Biotechnology ETF 0.49

BlackRock Advantage Small Cap Core Instl 0.45

Emerald Growth A 0.45

Wellington Global Hlthcr Eq USD G Ac 0.43

Fidelity Extended Market Index 0.43

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

Trevi Therapeutics Inc Market Status

Strong Buy: 7

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Trevi Therapeutics Inc Fundamentals

Market Cap 1362.30 M

PB Ratio 7.2294

PE Ratio 0.0

Enterprise Value 1174.79 M

Total Assets 193.44 M

Volume 2296889

Trevi Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-26749000 -26.7M, FY22:-29152000 -29.2M, FY21:-33940000 -33.9M, FY20:-32758000 -32.8M, FY19:-26050000 -26.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-38000 -0.0M, Q1/2025:-37000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-38000 -0.0M

Quarterly Net worth Q3/2025:-11802000 -11.8M, Q2/2025:-12301000 -12.3M, Q1/2025:-10340000 -10.3M, Q3/2024:-13242000 -13.2M, Q2/2024:-12352000 -12.4M

About Trevi Therapeutics Inc & investment objective

Company Information Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Organisation Biotechnology

Employees 34

Industry Biotechnology

CEO Ms. Jennifer L. Good

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Trevi Therapeutics Inc FAQs

What is the share price of Trevi Therapeutics Inc today?

The current share price of Trevi Therapeutics Inc is $10.59.

Can I buy Trevi Therapeutics Inc shares in India?

Yes, Indian investors can buy Trevi Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Trevi Therapeutics Inc shares in India?

You can easily invest in Trevi Therapeutics Inc shares from India by:

Can I buy fractional shares of Trevi Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Trevi Therapeutics Inc?

Trevi Therapeutics Inc has a market cap of $1362.30 M.

In which sector does Trevi Therapeutics Inc belong?

Trevi Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Trevi Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Trevi Therapeutics Inc?

The PE ratio of Trevi Therapeutics Inc is N/A and the PB ratio is 7.23.